Navigation For Mobile

Category Archives: Orphan drug

The Unblockbuster – Speeding Cures with Specialty Drugs

For years, industry soothsayers have suggested the imminent demise of blockbuster drugs was upon us (here’s one from 2009 – Goodbye blockbuster medicines; hello new pharmaceutical business models). But two…

Posted in blockbuster, CRO/CMO, drugs, generic, Orphan drug | Tagged , , , | Comments Off on The Unblockbuster – Speeding Cures with Specialty Drugs

Inside Neuland Technology: Bosentan Monohydrate

Pulmonary arterial hypertension (PAH) is a rare disease affecting 1-2 people per million in the U.S. and Europe. The orphan drug Bosentan, a dual endothelin receptor antagonist, is used in…

Posted in API synthesis, APIs, Capabilities, Chemistry, Contract Manufacturing, drugs, generic, method development, Neuland Labs, Orphan drug | Tagged , , | Comments Off on Inside Neuland Technology: Bosentan Monohydrate

Orphan Drug Manufacturing: Less Lifecycle Management, More Process Optimization

Rare (or orphan) diseases may sound like a small, low-prevalence problem – hence their labeling as ‘rare.’ But with 7,000+ rare diseases having already been identified, affecting more than 50…

Posted in Chemistry, Contract Manufacturing, Neuland Labs, Orphan drug | Comments Off on Orphan Drug Manufacturing: Less Lifecycle Management, More Process Optimization

What are the Key Differences with Orphan Drug Manufacturing?

I was asked recently what a contract manufacturer such as Neuland Labs saw as the key differences with orphan drug projects. Neuland approaches orphan drug projects slightly differently from our…

Posted in deuterium exchange, drugs, FDA, Orphan drug | Comments Off on What are the Key Differences with Orphan Drug Manufacturing?